PLEASANTON, Calif., Sept. 10, 2012 (GLOBE NEWSWIRE) -- ZELTIQ Aesthetics, Inc. (Nasdaq:ZLTQ) a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced that Mike Genau, President of its North American Franchise (NAF), has resigned from the company, effective September 21st, to pursue a new career opportunity, and will work with management to ensure a smooth transition process. Mark Foley, President and Chief Executive Officer, said, "Since Mike joined ZELTIQ earlier this year, he has worked closely with senior management to successfully implement a number of changes that have both strengthened and improved the productivity of our north american sales organization. This success was evidenced by the traction we showed in our second quarter results. Mike leaves behind a well organized sales team, with clearly defined goals and objectives, and we have great confidence that they will continue to execute as we search for new sales leadership. On behalf of the Board of Directors, I would like to thank Mike for the contributions he has made to ZELTIQ and wish him luck in his new endeavor. We remain committed to building out a best-in-class leadership team that can assist us in achieving our long-term growth objectives." About ZELTIQ ZELTIQ® Aesthetics is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. The Company's first commercial product, the CoolSculpting® System, is designed to selectively reduce stubborn fat bulges that may not respond to diet or exercise. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. CoolSculpting utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis, without causing scar tissue or damage to the skin, nerves, or surrounding tissues. ZELTIQ developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer within a treated fat bulge without requiring the patient to diet or exercise.